These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 23547267)

  • 21. Quantitative Susceptibility Mapping of Brain Iron and β-Amyloid in MRI and PET Relating to Cognitive Performance in Cognitively Normal Older Adults.
    Chen L; Soldan A; Oishi K; Faria A; Zhu Y; Albert M; van Zijl PCM; Li X
    Radiology; 2021 Feb; 298(2):353-362. PubMed ID: 33231528
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
    Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
    Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease.
    Chételat G; Villemagne VL; Pike KE; Ellis KA; Bourgeat P; Jones G; O'Keefe GJ; Salvado O; Szoeke C; Martins RN; Ames D; Masters CL; Rowe CC;
    Brain; 2011 Mar; 134(Pt 3):798-807. PubMed ID: 21310725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dynamic relationships between age, amyloid-β deposition, and glucose metabolism link to the regional vulnerability to Alzheimer's disease.
    Oh H; Madison C; Baker S; Rabinovici G; Jagust W
    Brain; 2016 Aug; 139(Pt 8):2275-89. PubMed ID: 27190008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease.
    Morris JC; Roe CM; Grant EA; Head D; Storandt M; Goate AM; Fagan AM; Holtzman DM; Mintun MA
    Arch Neurol; 2009 Dec; 66(12):1469-75. PubMed ID: 20008650
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationships Between Executive Control Circuit Activity, Amyloid Burden, and Education in Cognitively Healthy Older Adults.
    Karim HT; Tudorascu DL; Cohen A; Price JC; Lopresti B; Mathis C; Klunk W; Snitz BE; Aizenstein HJ
    Am J Geriatr Psychiatry; 2019 Dec; 27(12):1360-1371. PubMed ID: 31402087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brain Amyloid Deposition and Longitudinal Cognitive Decline in Nondemented Older Subjects: Results from a Multi-Ethnic Population.
    Gu Y; Razlighi QR; Zahodne LB; Janicki SC; Ichise M; Manly JJ; Devanand DP; Brickman AM; Schupf N; Mayeux R; Stern Y
    PLoS One; 2015; 10(7):e0123743. PubMed ID: 26221954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not β-amyloid in cognitively normal older individuals.
    Wirth M; Madison CM; Rabinovici GD; Oh H; Landau SM; Jagust WJ
    J Neurosci; 2013 Mar; 33(13):5553-63. PubMed ID: 23536070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between cerebrospinal fluid biomarkers of Alzheimer's disease and cognition in cognitively normal older adults.
    Pettigrew C; Soldan A; Moghekar A; Wang MC; Gross AL; O'Brien R; Albert M
    Neuropsychologia; 2015 Nov; 78():63-72. PubMed ID: 26394023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study.
    Leuzy A; Chiotis K; Hasselbalch SG; Rinne JO; de Mendonça A; Otto M; Lleó A; Castelo-Branco M; Santana I; Johansson J; Anderl-Straub S; von Arnim CA; Beer A; Blesa R; Fortea J; Herukka SK; Portelius E; Pannee J; Zetterberg H; Blennow K; Nordberg A
    Brain; 2016 Sep; 139(Pt 9):2540-53. PubMed ID: 27401520
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement.
    Ossenkoppele R; Zwan MD; Tolboom N; van Assema DM; Adriaanse SF; Kloet RW; Boellaard R; Windhorst AD; Barkhof F; Lammertsma AA; Scheltens P; van der Flier WM; van Berckel BN
    Brain; 2012 Jul; 135(Pt 7):2115-25. PubMed ID: 22556189
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease.
    Quiroz YT; Sperling RA; Norton DJ; Baena A; Arboleda-Velasquez JF; Cosio D; Schultz A; Lapoint M; Guzman-Velez E; Miller JB; Kim LA; Chen K; Tariot PN; Lopera F; Reiman EM; Johnson KA
    JAMA Neurol; 2018 May; 75(5):548-556. PubMed ID: 29435558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 11C-PiB imaging of human immunodeficiency virus-associated neurocognitive disorder.
    Ances BM; Benzinger TL; Christensen JJ; Thomas J; Venkat R; Teshome M; Aldea P; Fagan AM; Holtzman DM; Morris JC; Clifford DB
    Arch Neurol; 2012 Jan; 69(1):72-7. PubMed ID: 22232345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decline in cognitive function over 18 months in healthy older adults with high amyloid-β.
    Ellis KA; Lim YY; Harrington K; Ames D; Bush AI; Darby D; Martins RN; Masters CL; Rowe CC; Savage G; Szoeke C; Villemagne VL; Maruff P;
    J Alzheimers Dis; 2013; 34(4):861-71. PubMed ID: 23302660
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Subjective cognitive complaints and amyloid burden in cognitively normal older individuals.
    Amariglio RE; Becker JA; Carmasin J; Wadsworth LP; Lorius N; Sullivan C; Maye JE; Gidicsin C; Pepin LC; Sperling RA; Johnson KA; Rentz DM
    Neuropsychologia; 2012 Oct; 50(12):2880-2886. PubMed ID: 22940426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. β-Amyloid burden in healthy aging: regional distribution and cognitive consequences.
    Rodrigue KM; Kennedy KM; Devous MD; Rieck JR; Hebrank AC; Diaz-Arrastia R; Mathews D; Park DC
    Neurology; 2012 Feb; 78(6):387-95. PubMed ID: 22302550
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Baseline cognition is the best predictor of 4-year cognitive change in cognitively intact older adults.
    Schaeverbeke JM; Gabel S; Meersmans K; Luckett ES; De Meyer S; Adamczuk K; Nelissen N; Goovaerts V; Radwan A; Sunaert S; Dupont P; Van Laere K; Vandenberghe R
    Alzheimers Res Ther; 2021 Apr; 13(1):75. PubMed ID: 33827690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cognitive profile of amyloid burden and white matter hyperintensities in cognitively normal older adults.
    Hedden T; Mormino EC; Amariglio RE; Younger AP; Schultz AP; Becker JA; Buckner RL; Johnson KA; Sperling RA; Rentz DM
    J Neurosci; 2012 Nov; 32(46):16233-42. PubMed ID: 23152607
    [TBL] [Abstract][Full Text] [Related]  

  • 40. APOE modifies the association between Aβ load and cognition in cognitively normal older adults.
    Kantarci K; Lowe V; Przybelski SA; Weigand SD; Senjem ML; Ivnik RJ; Preboske GM; Roberts R; Geda YE; Boeve BF; Knopman DS; Petersen RC; Jack CR
    Neurology; 2012 Jan; 78(4):232-40. PubMed ID: 22189452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.